Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Interim data from a phase II immunotherapy study evaluating Oxxon Therapeutics' PrimeBoost technology in patients with advanced melanoma have shown the treatment to be safe and effective.
Subscribe to our email newsletter
Oxxon’s proprietary PrimeBoost platform is an approach that allows rapid development of products to selectively stimulate and enhance a potent cellular response.
The recent phase II study showed PrimeBoost’s potential to produce an immune response in patients and evidence of an anti-tumor response. The treatment was also seen to be safe and well-tolerated.
In this study, 25% of the stage III and IV patients enrolled were stable up to week 16. In addition, one stage III patient showed a partial clinical response which was sustained up to week 72 following further MVA boosting. This patient also showed a striking immunological response.
Overall, 29% of the immunologically evaluable patients showed melanoma-specific cellular immune responses. Three of these patients (10%) showed a T-cell response to more than one epitope. Interestingly, all stage III melanoma patients showed a confirmed immunological response.
“These data continue to support PrimeBoost’s ability to elicit a melanoma-specific immune response and support future development of the current melanoma immunotherapeutics, particularly in stage III patients,” said Dr Deirdre Gillespie, CEO at Oxxon.